![](/images/graphics-bg.png)
48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
المؤلفون المشاركون
Xiang, Zhu
Peng, Liang
Xie, Dongying
Xie, Chan
Zhao, Zhixin
Lin, Chao-shuang
Xu, Wen-xiong
Gao, Zhi L.
Deng, Hong
Zhang, Qian
Chen, You-ming
Mei, Yong-yu
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-10
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Background and Aims.
We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment.
Methods.
A total of 92 patients were enrolled in this prospective study.
Patients were monitored every month for the first 3 months after cessation and every 3 months thereafter.
Results.
Sixty-two patients finished 48 weeks of follow-up.
None died or developed liver failure, cirrhosis, or HCC.
The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse.
Virologic relapses occurred in 39 (62.9%) patients, with 72.7% occurring in the first 24 weeks in origin HBeAg positive patients and 82.4% in the first 12 weeks in origin HBeAg negative patients.
Age (OR = 1.06, 95% CI = 1.02–1.10; p=0.003), the HBsAg level (OR = 2.21, 95% CI = 1.47–3.32; p<0.001), and positive origin HBeAg status (OR = 0.32, 95% CI = 0.14–0.74; p=0.008) were predictive factors to virologic relapse.
HBV DNA level (OR = 1.34, 95% CI = 1.13–1.58; p<0.001) was predictive factor to retreatment.
Conclusions.
NA cessation is safe under supervision.
Age, HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse.
The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Xu, Wen-xiong& Zhang, Qian& Xiang, Zhu& Lin, Chao-shuang& Chen, You-ming& Deng, Hong…[et al.]. 2018. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130878
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Xu, Wen-xiong…[et al.]. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1130878
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Xu, Wen-xiong& Zhang, Qian& Xiang, Zhu& Lin, Chao-shuang& Chen, You-ming& Deng, Hong…[et al.]. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130878
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130878
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)